GOFUS, Jan, Petr FILA, Martin VOBORNIK, Jiri ONDRASEK, Petr NĚMEC, Jan ŠTĚRBA, Eva CERMAKOVA, Martin TUNA and Jan VOJACEK. Unicuspid Aortic Valve in Patients Undergoing the Ross Procedure. Annals of Thoracic Surgery. New York: Elsevier Science Inc., 2023, vol. 115, No 3, p. 626-631. ISSN 0003-4975. Available from: https://dx.doi.org/10.1016/j.athoracsur.2022.03.061.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Unicuspid Aortic Valve in Patients Undergoing the Ross Procedure
Authors GOFUS, Jan (203 Czech Republic), Petr FILA (203 Czech Republic, guarantor, belonging to the institution), Martin VOBORNIK (203 Czech Republic), Jiri ONDRASEK (203 Czech Republic), Petr NĚMEC (203 Czech Republic, belonging to the institution), Jan ŠTĚRBA (203 Czech Republic, belonging to the institution), Eva CERMAKOVA (203 Czech Republic), Martin TUNA (203 Czech Republic) and Jan VOJACEK (203 Czech Republic).
Edition Annals of Thoracic Surgery, New York, Elsevier Science Inc. 2023, 0003-4975.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.600 in 2022
RIV identification code RIV/00216224:14110/23:00130667
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.athoracsur.2022.03.061
UT WoS 000944472800001
Keywords in English Unicuspid Aortic Valve; Ross Procedure
Tags 14110911, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 27/4/2023 13:31.
Abstract
BACKGROUND The prevalence and outcomes of the unicuspid aortic valve (UAV) in patients undergoing the Ross procedure have been strongly underreported in the current literature. We sought to evaluate this in comparison with bicuspid (BAV) and tricuspid valve (TAV) in our Ross cohort.METHODS This was a retrospective observational study of patients undergoing the Ross procedure at 2 dedicated centers between 2009 and 2020. Primary end points were the risks of midterm autograft reoperation and the onset of at least moderate aortic regurgitation during follow-up. The secondary end point was to compare the perioperative out-comes between the groups.RESULTS Included in the analysis were 286 patients, of those 39% with UAV, 52% with BAV, and 9% with TAV. UAV patients were operated on at the youngest age (P < .001) and more often for a combined hemodynamic aortic valve pathology (P = .02). They had the largest aortic root dimensions: annulus (P = .01), Valsalva sinuses (P = .11), sino-tubular junction (P = .001), and ascending aorta (P < .0001). The risks of reoperation (P = .86) and the onset of aortic regurgitation (P = .75) were comparable among the groups over the follow-up of 4.1 years. There was no difference in perioperative outcomes.CONCLUSIONS UAV is a separate unit characterized by a distinct hemodynamic pathology and generated aortopathy. It is not associated with a higher risk of reoperation or new onset of aortic regurgitation after the Ross procedure in the midterm postoperatively. At the current state, UAV remains acceptable for the Ross procedure.
PrintDisplayed: 22/7/2024 07:29